Allscripts (MDRX) Misses Q3 EPS by 1c; Guides Q4 EPS Below Views

Allscripts (NASDAQ: MDRX) reported Q3 EPS of $0.14, $0.01 worse than the analyst estimate of $0.15. Revenue for the quarter came in at $392 million versus the consensus estimate of $414.92 million.

GUIDANCE:

Allscripts sees Q4 2016 EPS of $0.14-$0.16, versus the consensus of $0.17. Allscripts sees Q4 2016 revenue of $420-435 million, versus the consensus of $425.4 million.

For earnings history and earnings-related data on Allscripts (MDRX) click here.

You May Also Be Interested In

• Crown Castle (CCI) Tops Q1 EPS by 1c; maintains outlook for FY24
• Abbott Laboratories (ABT) narrows 2024 earnings guidance, shares slip
• Equifax (EFX) Tops Q1 EPS by 6c, Misses on Revenue; Offers Guidance